Literature DB >> 16634114

Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control.

Sónia Benítez1, Antonio Pérez, José Luis Sánchez-Quesada, Ana María Wagner, Mercedes Rigla, Rosa Arcelus, Oscar Jorba, Jordi Ordóñez-Llanos.   

Abstract

BACKGROUND: The physicochemical and biological characteristics of electronegative low-density lipoprotein (LDL) (LDL(-)) from type 2 diabetic patients (DM2), before and after insulin therapy, were studied.
METHODS: Total LDL was subfractionated in LDL(+) (native LDL) and LDL(-) by anion-exchange chromatography.
RESULTS: The proportion of LDL(-) was increased in plasma from DM2 patients compared to control subjects (13.8 +/- 4.6% versus 6.1 +/- 2.5, P < 0.05) and was not modified after glycemic optimization (14.0 +/- 5.9%). LDL(-) from DM2 patients presented similar differential characteristics versus LDL(+) than LDL(-) from controls; that is, decreased apoB and oxidizability, and increased triglyceride, nonesterified fatty acids (NEFA), apoE, apoC-III, platelet-activating factor (PAF) acetylhydrolase activity and aggregability. No difference in particle size, antioxidants, malondialdehyde (MDA), fructosamine or glycated low-density lipoprotein (gLDL) was observed between LDL subfractions. Concerning differences between LDL subfractions isolated from DM2 and from control subjects, the former showed increased MDA, fructosamine and gLDL proportion and decreased LDL size and antioxidant content. The only effect of glycemic optimization was a decrease in fructosamine and gLDL in LDL(+) from DM2 subjects. LDL(-) from DM2 patients presented low binding affinity to the low-density lipoprotein receptor (LDLr) in cultured fibroblasts compared to LDL(+) and two- to threefold increased ability to release interleukin-8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) in endothelial cells.
CONCLUSION: These results suggest that, although nonenzymatic glycosylation and oxidation are increased in type 2 diabetes, these features would not be directly involved in the generation of LDL(-). Moreover, LDL(-) properties suggest that the high proportion observed in plasma could promote accelerated atherosclerosis in DM2 patients through increased residence time in plasma and induction of inflammatory responses in artery wall cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16634114     DOI: 10.1002/dmrr.643

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

1.  Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study.

Authors:  Bo Zhang; Akira Matsunaga; David L Rainwater; Shin-Ichiro Miura; Keita Noda; Hiroaki Nishikawa; Yoshinari Uehara; Kazuyuki Shirai; Masahiro Ogawa; Keijiro Saku
Journal:  J Lipid Res       Date:  2008-12-03       Impact factor: 5.922

Review 2.  Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

Authors:  Jun Panee
Journal:  Cytokine       Date:  2012-07-04       Impact factor: 3.861

3.  Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Authors:  Shobini Jayaraman; Olivia R Chavez; Antonio Pérez; Inka Miñambres; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-04-11       Impact factor: 4.698

Review 4.  Oxidized low-density lipoprotein.

Authors:  Sampath Parthasarathy; Achuthan Raghavamenon; Mahdi Omar Garelnabi; Nalini Santanam
Journal:  Methods Mol Biol       Date:  2010

Review 5.  The underlying chemistry of electronegative LDL's atherogenicity.

Authors:  Liang-Yin Ke; Nicole Stancel; Henry Bair; Chu-Huang Chen
Journal:  Curr Atheroscler Rep       Date:  2014-08       Impact factor: 5.113

Review 6.  Electronegative LDL: a circulating modified LDL with a role in inflammation.

Authors:  Montserrat Estruch; José Luis Sánchez-Quesada; Jordi Ordóñez Llanos; Sònia Benítez
Journal:  Mediators Inflamm       Date:  2013-08-22       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.